ERBB2 AMPLIFICATION LEVEL AND PTPN2 GAIN AS POTENTIAL PROGNOSTIC FACTORS IN METASTATIC HER2-POSITIVE BREAST CANCER TREATED WITH TRASTUZUMAB

被引：0
|
作者：
Ellegard, Sander [1 ]
Veenstra, Cynthia [1 ]
Perez-Tenorio, Giseh [1 ]
Hallbeck, Anna-Lotta [1 ]
Elander, Nils [1 ]
Stal, Olle [1 ]
机构：
[1] Univ Hosp Linkoping, Oncol, Linkoping, Sweden
来源：
BREAST | 2017年 / 36卷
关键词：
D O I：
10.1016/S0960-9776(17)30690-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO71
引用
收藏
页码：S46 / S46
页数：1
相关论文
共 50 条
  • [41] Duration of trastuzumab for HER2-positive breast cancer
    Montemurro, Filippo
    Aglietta, Massimo
    LANCET ONCOLOGY, 2013, 14 (08): : 678 - 679
  • [42] Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab
    Fujita, Noriko
    Enomoto, Yukie
    Inakami, Keiko
    Yanagisawa, Tetsu
    Iguchi, Chikage
    Aono, Toyokazu
    Nomura, Takashi
    Yamamoto, Hitoshi
    Kasugai, Tsutomu
    Shiba, Eiichi
    ONCOLOGY, 2020, 98 (01) : 35 - 41
  • [43] Trastuzumab (herceptin) and HER2-positive breast cancer
    Murray, S
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2006, 174 (01) : 36 - 37
  • [44] Trastuzumab emtansine for HER2-positive breast cancer
    Venkatesan, Priya
    LANCET ONCOLOGY, 2016, 17 (12): : E528 - E528
  • [45] Adjuvant trastuzumab for HER2-positive breast cancer
    Spicer, J
    Harries, M
    Ellis, P
    LANCET, 2005, 366 (9486): : 634 - 634
  • [46] HER2-Positive Breast Cancer: Beyond Trastuzumab
    Murphy, Conleth G.
    Fornier, Monica
    ONCOLOGY-NEW YORK, 2010, 24 (05): : 410 - 415
  • [47] Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: A pilot study
    Repka, T
    Chiorean, EG
    Gay, J
    Herwig, KE
    Kohl, VK
    Yee, D
    Miller, JS
    CLINICAL CANCER RESEARCH, 2003, 9 (07) : 2440 - 2446
  • [48] HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1
    Braso-Maristany, Fara
    Griguolo, Gaia
    Chic, Nuria
    Pascual, Tomas
    Pare, Laia
    Maues, Julia
    Galvan, Patricia
    Dieci, Maria Vittoria
    Miglietta, Federica
    Giarratano, Tommaso
    Martinez-Saez, Olga
    Marin-Aguilera, Mercedes
    Schettini, Francesco
    Conte, Benedetta
    Angelats, Laura
    Vidal, Maria
    Adamo, Barbara
    Munoz, Montserrat
    Sanfeliu, Esther
    Gonzalez, Blanca
    Vivancos, Ana
    Villagrasa, Patricia
    Parker, Joel S.
    Perou, Charles M.
    Conte, PierFranco
    Prat, Aleix
    Guarneri, Valentina
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2023, 115 (03): : 332 - 336
  • [49] Presentation and treatment of HER2-positive metastatic breast cancer patients already treated with adjuvant trastuzumab
    Yuri Torrejon, Davis
    Di Cosimo, Serena
    Sanchez-Olle, Gessami
    Balmana, Judith
    Bellet, Meritxell
    Gomez, Patricia
    Saura, Cristina
    Manuel Perez-Garcia, Jose
    Munoz-Couselo, Eva
    Vidal, Maria
    Ortega, Vanesa
    De Mattos-Arruda, Leticia
    Oliveira, Mafalda
    Mulet-Margalef, Nuria
    Tabernero, Josep
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Tucatinib Plus Trastuzumab and Capecitabine for ERBB2 (HER2)-Positive Metastatic Breast Cancer With Brain Metastases-Reply
    Lin, Nancy U.
    JAMA ONCOLOGY, 2023, 9 (07) : 1009 - 1009
12345